GeoVax Labs, Inc. will report financial results for the quarter ended September 30, 2025, after market close on November 13, 2025. Management will host a conference call and webcast at 4:30 p.m. ET to review results and provide a business update, offering investors crucial insights into the company's financial health and clinical progress. The announcement holds significance for stakeholders monitoring GeoVax's advancement in developing innovative vaccine technologies across multiple disease areas.
The company's lead clinical program, GEO-CM04S1, represents a next-generation COVID-19 vaccine currently undergoing three Phase 2 clinical trials. These trials evaluate the vaccine as a primary option for immunocompromised patients, including those with hematologic cancers who respond inadequately to current authorized vaccines. Additional studies examine GEO-CM04S1 as a booster for chronic lymphocytic leukemia patients and as a more robust, durable COVID-19 booster for healthy individuals previously vaccinated with mRNA vaccines. The progression of these trials represents important milestones in addressing vaccination challenges for vulnerable populations.
In oncology, GeoVax's lead program focuses on Gedeptin®, a novel oncolytic solid tumor gene-directed therapy that recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The company also develops a vaccine targeting Mpox and smallpox, which based on recent European Medicines Agency regulatory guidance, may progress directly to Phase 3 clinical evaluation, bypassing earlier trial phases. This regulatory pathway acceleration could significantly impact the development timeline for this important vaccine candidate.
Investors can access the live audio webcast through the Company's Investor Relations website or register for the conference call using the provided registration link. The webcast archive will be available approximately two hours after the call concludes and remain accessible for at least 90 days, allowing investors who miss the live presentation to review the information at their convenience. The company maintains worldwide rights for its technologies and products, supported by a strong intellectual property portfolio that underpins its long-term strategic position in the biotechnology sector.
